Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety — Oct 16th, 2024

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024

Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024

ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...